IP Library Granted Patent US 11,679,124
Granted Patent B2
US 11,679,124 · App. 16/982,529 · Granted Jun 20, 2023

Composition for use in the treatment of conditions caused by calcium deficiency

Inventors: Lars Fändriks (Askim, SE); Ville Wallenius (Mölndal, SE)
Assignee: Epicyt Pharma AB
A61K33/06A23L33/155A23L33/16A61K31/201A61K31/592A61K9/0019A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,679,124
App. No.
16/982,529
Granted
Jun 20, 2023
Kind
B2
Abstract

The present invention is related to a composition comprising at least one bile acid; at least one fatty acid or salt thereof, calcium, and vitamin D, for use as a medicament, and especially in inducing expression of vitamin D-receptor co-activator Hsp90β for increasing vitamin D-induced calcium uptake in a mammal. The invention is also related to a dietary or nutritional supplement comprising a composition as described above and comprising additionally conventional components for dietary or nutritional supplements.

Claims (22)

1. A method for treating a calcium absorption deficiency in a patient comprising administering to said patient an amount of a composition comprising

glycocholic acid (GCA), or a salt thereof, and

butyric acid, or a salt thereof.

2. A method for treating osteoporosis, calcium malabsorption conditions or bone disorders in a patient comprising administering to said patient an amount of a composition comprising

glycocholic acid (GCA), or a salt thereof, and

butyric acid, or a salt thereof.

3. A method for reducing bone mineral density (BMD) loss in a patient comprising administering to said patient an amount of a composition comprising

glycocholic acid (GCA), or a salt thereof, and

butyric acid, or a salt thereof.

4. The method of claim 1 , wherein the patient is a Roux-en-Y gastric bypass (RYGB) patient or a sleeve gastrectomy (SG) patient.

5. The method of claim 1 , wherein the composition further comprises vitamin D, and wherein the vitamin D in the composition is present in an amount equal to the recommended daily intake (RDI) or less.

6. The method of claim 1 , wherein the composition further comprises calcium, and wherein the calcium in the composition is present in an amount equal to the recommended daily intake (RDI) or less.

7. The method according to claim 5 , wherein the vitamin D comprises vitamin D3.

8. The method according to claim 6 , wherein the calcium is calcium carbonate, calcium citrate, calcium phosphate or mixtures thereof.

9. The method according to claim 1 , wherein the composition further comprises at least one of a vehicle, excipient, lubricant, flavour, sweetener, binder, or disintegrant.

10. The method according to claim 1 , wherein the composition is formulated for oral delivery, parenteral delivery, intravenous infusion, or injection.

11. The method according to claim 1 , wherein the composition is in solid form.

12. The method according to claim 1 , wherein the composition is formulated as a powder, pill, tablet, or capsule.

13. The method according to claim 1 , wherein the composition is a nutritional or dietary supplement.

14. The method of claim 1 , wherein the composition further comprises oleic acid, or a salt thereof.

15. The method of claim 2 , wherein the composition further comprises oleic acid, or a salt thereof.

16. The method of claim 3 , wherein the composition further comprises oleic acid, or a salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2020
From: FANDRIKS, LARS; WALLENIUS, VILLE
To: EPICYT PHARMA AB
Reel/Frame 054009/0633 →
Priority Claims (1)
SE 1850304-5 · Mar 19, 2018 · national
Continuity (1)
Related Publication 20210000864A1 · Jan 7, 2021